The sensitive, reproducible and high-throughput nature of immunoassays make them especially well-suited to characterize immunogenicity, neutralization and pharmacodynamic responses of candidate biologics. Pre-existing immunity, cross- reactivity and non-specific binding can be identified during screening while longitudinal monitoring allows innovators to observe the modulatory effects of their treatment regime along with possible inactivation of the intended therapeutic effect While colorimetric ELISAs are essential for many programs, detection technologies such as magnetic beads, biolayer interferometry, electrochemiluminescence and fluorescence have provided the means to extend the dynamic range of an assay, limit matrix interference and to multiplex anywhere from 2 to 100 analytes. Advantages range from sample conservation to increased precision, reproducibility and data capacity, aiding developers across all stages of the product development pathway.

ELISA contract research analysis

ABL's immunoassay authorities can provide:

ABL’s decades of experience in antigen & antibody binding assays include:

  • ELISA- Quantitative, Semi-quantitative or Qualitative
  • Electrochemiluminescent (ECL) Multiplex Analysis
  • Anti-Drug Antibody Assays (ADA)
  • Binding Affinity
  • Epitope Binning
  • Antibody Isotyping
  • Other needs? Inquire here
ELISA plate reader

Applications of immunoassays:


Preclinical Characterization of Humoral Immune Responses 

ABL’s platform agnosticism drives our experts to match the best technology and instrumentation solutions to perfectly complement your study requirements.

Immunoassay Technology Suite:

Interested in speaking to a scientist about immunoassays?

Learn more about how ABL can also support your: